ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc (VNDA)

6.11
0.04
(0.66%)
Closed July 21 4:00PM
6.12
0.01
(0.16%)
After Hours: 5:26PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
6.12
Bid
5.94
Ask
6.12
Volume
531,480
5.94 Day's Range 6.14
3.295 52 Week Range 6.75
Market Cap
Previous Close
6.07
Open
6.09
Last Trade Time
Financial Volume
$ 3,226,208
VWAP
6.0702
Average Volume (3m)
1,227,535
Shares Outstanding
58,198,273
Dividend Yield
-
PE Ratio
141.53
Earnings Per Share (EPS)
0.04
Revenue
192.64M
Net Profit
2.51M

About Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder... Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include Tradipitant (VLY-686), VTR-297, and VQW-765. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Vanda Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VNDA. The last closing price for Vanda Pharmaceuticals was $6.07. Over the last year, Vanda Pharmaceuticals shares have traded in a share price range of $ 3.295 to $ 6.75.

Vanda Pharmaceuticals currently has 58,198,273 shares outstanding. The market capitalization of Vanda Pharmaceuticals is $353.26 million. Vanda Pharmaceuticals has a price to earnings ratio (PE ratio) of 141.53.

VNDA Latest News

Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex

Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex PR Newswire WASHINGTON, July 1, 2024 WASHINGTON, July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc...

Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders

Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders PR Newswire WASHINGTON, June 19...

Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak

Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak PR Newswire WASHINGTON, June 13, 2024 No Shareholder Action Required at This Time WASHINGTON, June...

Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.

Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd. PR Newswire WASHINGTON, June 6, 2024 No Shareholder Action Required at...

Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference

Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference PR Newswire WASHINGTON, May 30, 2024 WASHINGTON, May 30, 2024 /PRNewswire/ -- Vanda...

Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®

Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY® PR Newswire WASHINGTON, May 30, 2024 WASHINGTON, May 30, 2024 /PRNewswire/ -- Vanda...

Vanda Pharmaceuticals Announces Presentations at SLEEP 2024

Vanda Pharmaceuticals Announces Presentations at SLEEP 2024 PR Newswire WASHINGTON, May 29, 2024 WASHINGTON, May 29, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.233.904923599325.896.335.758950566.09409702CS
40.142.341137123755.986.335.138264255.78668191CS
121.5533.91684901534.576.754.4512275355.65102412CS
262.4365.85365853663.696.753.4617655144.98935847CS
52-0.26-4.075235109726.386.753.29514152504.7901886CS
156-12.155-66.51162790718.27521.43993.2958151757.29730948CS
260-7.17-53.950338600513.2921.86273.2957188009.33090923CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SERVServe Robotics Inc
$ 7.51
(185.55%)
262.73M
AUGXAugmedix Inc
$ 2.27
(147.71%)
21.87M
XCURExicure Inc
$ 0.5351
(76.02%)
14.02M
PSNLPersonalis Inc
$ 3.83
(56.33%)
22.76M
MDBHMDB Capital Holdings LLC
$ 10.675
(37.21%)
126.13k
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
124.61M
HYZNHyzon Motors Inc
$ 0.149
(-47.54%)
23.63M
MEDSTRxADE Health Inc
$ 14.92
(-33.45%)
223.27k
SILOSilo Pharma Inc
$ 2.50
(-27.95%)
11.93M
KITTNauticus Robotics Inc
$ 0.0935
(-27.46%)
28.43M
SERVServe Robotics Inc
$ 7.51
(185.55%)
262.73M
NVDANVIDIA Corporation
$ 117.93
(-2.61%)
206.41M
SXTP60 Degrees Pharmaceuticals Inc
$ 0.2602
(5.77%)
202.14M
SQQQProShares UltraPro Short QQQ
$ 8.46
(2.79%)
184.21M
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
119.98M

VNDA Discussion

View Posts
harry crumb harry crumb 2 weeks ago
Watching this closely
👍️0
Monksdream Monksdream 3 weeks ago
VNDA under $10
👍️0
Monksdream Monksdream 1 month ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
Monksdream Monksdream 2 months ago
Over $6
👍️0
tw0122 tw0122 2 months ago
Vanda acquired U.S. and Canadian rights to PONVORY® from a Johnson & Johnson Company on December 7, 2023. PONVORY® is approved by the U.S. Food and Drug Administration (FDA) and Health Canada to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease (RMS).

In anticipation of the commercial launch of PONVORY® for RMS in the third quarter of 2024, Vanda is initiating a host of commercial activities including the creation of a specialty sales force, a prescriber awareness program and a comprehensive marketing program.
👍️0
harry crumb harry crumb 2 months ago
Gonna be a winner. Patience
👍️0
harry crumb harry crumb 2 months ago
Over 5$!
👍️0
Monksdream Monksdream 3 months ago
VNDA under $5
👍️0
harry crumb harry crumb 3 months ago
Let er rip $$$$$$$$
👍️0
Tiger Money Tiger Money 3 months ago
Agreed. This could double quickly
👍️0
philaya philaya 3 months ago
got this today...
very good trades.
👍️0
harry crumb harry crumb 3 months ago
This little gem could run up fast, they obviously have their science going in the right direction as the offers are there just not the price, could be a 10.00 offer in the works
👍️0
morokoy morokoy 3 months ago
Shares Outstanding 57,537,499 shares
Insider Shares 7,908,897 shares
Insider Ownership 13.75 %
Total Insiders 34
👍️0
morokoy morokoy 3 months ago
"The dividend distribution of rights will be payable to stockholders of record as of the close of business on April 29, 2024."

A shareholder may also receive distributions such as additional stock or stock rights in the distributing corporation; such distributions may or may not qualify as dividends.

A shareholder may also receive distributions such as additional stock or stock rights in the distributing corporation; such distributions may or may not qualify as dividends. You should receive a Form 1099-DIV, Dividends and Distributions from each payer for distributions of at least $10.

Guess we'll have to wait on the promised 8K.

Additional details of the Rights Plan will be contained in a Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC"). The filing will be available on the SEC's website at www.sec.gov.
👍️0
harry crumb harry crumb 3 months ago
Minimum 8$ imo
👍️0
MiamiGent MiamiGent 3 months ago
Vanda Pharmaceuticals rejects takeover proposal from Future Pak
REUTERS
1 mins ago
April 17 (Reuters) - Vanda Pharmaceuticals Inc (VNDA.NaE) on Wednesday said it is rejecting a takeover proposal from Future Pak, a privately-held contract manufacturer and packager of pharmaceuticals, as it significantly undervalues the company.

(Reporting by Sriparna Roy in Bengaluru; Editing by Tasim Zahid)
👍️0
Monksdream Monksdream 3 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️ 1
MiamiGent MiamiGent 3 months ago
Probably...but I took it at 5.49
👍️0
Monksdream Monksdream 3 months ago
Will it grow legs after 9:30
👍️0
MiamiGent MiamiGent 3 months ago
VNDA Vol picking up..

$5.49 +$1.44 (+35.56%)

Volume 3,354,569

90 DAV... 2M
👍️0
MiamiGent MiamiGent 3 months ago
VNDA Here we go
$5.3781 +$1.3281 (32.79%)

Bid ARCX
5.36 x 10
Ask XNMS
5.38 x 11
Volume
2,971,106
👍️0
MiamiGent MiamiGent 3 months ago
VNDA Vol is good. Already @ 90 DAV
Volume 2,056,421
10/90-day avg. volume
7M / 2M
👍️0
MiamiGent MiamiGent 3 months ago
VNDA Good post, Laster.
https://www.futurepak.com/
👍️0
Laster Laster 3 months ago
The major question is who is Future Pak really?
Is this a legit offer?
Either way, company is extremely undervalued with no debt (I believe) and lots of cash.
Large short position. Lots of selling PM at $5.
Market does not seem to believe this offer. Sorry.
👍️0
MiamiGent MiamiGent 3 months ago
VNDA Float 52.05M

Shares Short (3/28/2024) 2.49M
Short Ratio (3/28/2024) 2.78
Short % of Float (3/28/2024) 5.45%
👍️0
MiamiGent MiamiGent 3 months ago
VNDA
Bid EDGX
4.85 x 3
Ask EDGX
4.88 x 3

Volume
1,790,654
Avg Vol (10 day) 6.63M
👍️0
MiamiGent MiamiGent 3 months ago
Vanda Pharmaceuticals
Closed .01 (-0.25%)

Pre-market
$5.15 +1.10 (+27.16%)
As of Apr-17-2024 7:23:52 AM ET
Bid x size $5.14 x 1
Ask x size $5.16 x 3
👍️0
MiamiGent MiamiGent 3 months ago
VNDA In 5.12. Let's see, said the blind man.
👍️0
MiamiGent MiamiGent 3 months ago
Vanda Pharmaceuticals jumps 38% on Future Pak's latest buy offer
Apr. 17, 2024 6:41 AM ETVanda Pharmaceuticals Inc. (VNDA) Stock
👍️0
MiamiGent MiamiGent 3 months ago
What's the news?
👍️0
Awl416 Awl416 3 months ago
Damn
👍️0
Monksdream Monksdream 3 months ago
Will it grow legs after 9:30
👍️0
Monksdream Monksdream 4 months ago
Will it grow legs after 9:30
👍️0
tknuncle tknuncle 6 months ago
I have been acquiring since $3.90. I wish that I would have waited longer lol but, like what I see with VNDA. Was going to grab the last of my starter position soon. GLTA
👍️0
weedtrader420 weedtrader420 6 months ago
FDA Approve
👍️0
Triple nickle Triple nickle 8 months ago
Fda accepts new drug application for tradipitant in the after hours today
👍️ 1
jgrabar jgrabar 2 years ago
$VNDA -On May 19, 2022, Vanda Pharmaceuticals agreed to settle a securities fraud class action complaint (the “Complaint”) for $11.5 Million. https://grabarlaw.com/the-latest/vanda-pharmaceuticals-investigation/
👍️0
RNsidersbuying RNsidersbuying 4 years ago
VNDA 12.34 - FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome

https://ih.advfn.com/stock-market/NASDAQ/vanda-pharmaceuticals-VNDA/stock-news/83807075/fda-approves-hetlioz-tasimelteon-for-the-treatmen
👍️0
XenaLives XenaLives 4 years ago
Everything would be a lot better if the govt. would just let doctors treat COVID like another flu bug. The drama is getting old.
👍️0
Peepson Peepson 4 years ago
Yo, this thing is going to trade sideways for a while. They have a drug that could help with covid but so does every other pharma company. Its a safe hold imo but nothing will happen fast i don't think
👍️0
XenaLives XenaLives 4 years ago
What's up? Doesn't seem to be much interest. I was looking at the chart but haven't found much on the company yet.

👍️0
otcmoneydoubler otcmoneydoubler 4 years ago
LOL. VNDA GOT NEWS TODAY. SO WHAT DD HAVE YOU GOT TO SHARE?
👍️0
Peepson Peepson 4 years ago
Yo, does anyone still follow this board. I might have some interesting dd to share.
👍️0
bezen bezen 8 years ago
https://finance.yahoo.com/news/jefferies-5-top-biotech-stocks-133534894.html
👍️0
Coz Mabluda Coz Mabluda 8 years ago
Brett Jensen. SA article re VNDA. Expects positive analyst's review.

Vanda Pharmaceuticals (NASDAQ:VNDA) posted solid third quarter results on Thursday. Instead of losing a dime a share as expected, the company posted a profit of 11 cents a share. Revenue was also up more than 35% from the same period a year ago. The company now looks like it could be profitable in FY2017. I expect some positive analyst commentary on this name by analysts over the next week. Vanda has a solid pipeline and over $140 million in cash and marketable securities on the balance sheet. One has to like the company's growth trajectory and the concern seems undervalued with just a $600 million market capitalization.



👍️0
stocktrademan stocktrademan 8 years ago
fast and steady profit scan VNDA bullish 16.64



normal chart


log chart

👍️0
ClearlyStocks ClearlyStocks 8 years ago
VNDA $16.74
👍️0
ClearlyStocks ClearlyStocks 8 years ago
$VNDA $16 from $14 now
👍️0
nyctraydr nyctraydr 8 years ago
Where Things Stand For Vanda Pharmaceuticals In Fanapt Patent Suit http://marketexclusive.com/things-stand-vanda-pharmaceuticals-inc-nasdaqvnda-fanapt-patent-suit/24951/?icd1
👍️0
ClayTrader ClayTrader 8 years ago
* * $VNDA Video Chart 08-25-16 * *

Link to Video - click here to watch the technical chart video
👍️0

Your Recent History

Delayed Upgrade Clock